BTX-A51 clinical trials
Also written BTX-A51.
How each study uses BTX-A51 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BTX-A51 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BTX-A51
- 3
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test BTX-A51.
- Jan 2027BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaPhase 1 · Michael Wagner, MD
Studies
Open first, then newest update. How each study uses BTX-A51 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast CancerRecruitingPhase 1Edgewood Oncology Inc.NCT04872166Written as BTX-A51
- A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 1Edgewood Oncology Inc.NCT04243785Written as BTX-A51
- BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaActive, not recruitingPhase 1Michael Wagner, MDNCT06414434Written as BTX-A51
Codes
What other systems call BTX-A51 · ClinicalTrials.gg INT017133
- UNII (FDA) L46P54NB4VBTX-A51One source FDA
- NCI Thesaurus C169027CK1alpha/CDK7/CDK9 Inhibitor BTX-A51One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L46P54NB4V | BTX-A51 | One source FDA |
| NCI Thesaurus | C169027 | CK1alpha/CDK7/CDK9 Inhibitor BTX-A51 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.